title: Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability.
abstract: The aim of this study was to evaluate, in terms of dog macrophage killing ability in vitro, a vaccine based on Leishmania infantum promastigote soluble antigen (LSA) formulated with three different adjuvants (BCG, AdjuPrime, MPL/TDM/CWS). A significant increase of the macrophage killing ability was observed in dogs vaccinated with LSA+MPL/TDM/CWS after 1 month from vaccination. A similar increase of macrophage parasitocidal ability was present only after 5 months in dogs vaccinated with LSA+BCG or LSA+AdjuPrime. In all dogs the augmented killing percentage was still present after 12 months from vaccination. Therefore, in particular LSA+MPL/TDM/CWS vaccine seems promising for further studies in dogs.
authors.affiliation: Dipartimento di Scienze Biomediche, University of Foggia, Ospedali Riuniti, Italy. t.trotta@unifg.it
authors.forename: T
authors.initials: T
authors.lastname: Trotta
authors.forename: A
authors.initials: A
authors.lastname: Fasanella
authors.forename: D
authors.initials: D
authors.lastname: Scaltrito
authors.forename: L
authors.initials: L
authors.lastname: Gradoni
authors.forename: V
authors.initials: V
authors.lastname: Mitolo
authors.forename: O
authors.initials: O
authors.lastname: Brandonisio
authors.forename: A
authors.initials: A
authors.lastname: Acquafredda
authors.forename: M A
authors.initials: MA
authors.lastname: Panaro
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology / Q000627:therapeutic use; D017358:Cell Wall Skeleton / Q000276:immunology / Q000627:therapeutic use; D003311:Cord Factors / Q000276:immunology / Q000627:therapeutic use; D004283:Dog Diseases / Q000276:immunology* / Q000469:parasitology / Q000517:prevention & control; D004285:Dogs; D005260:Female; D006801:Humans; D018314:Leishmania infantum / Q000276:immunology*; D007896:Leishmaniasis / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D054332:Leishmaniasis Vaccines / Q000276:immunology / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008050:Lipid A / Q000031:analogs & derivatives / Q000276:immunology / Q000627:therapeutic use; D008264:Macrophages / Q000276:immunology*; D008297:Male; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D001500:BCG Vaccine; D017358:Cell Wall Skeleton; D003311:Cord Factors; D054332:Leishmaniasis Vaccines; D008050:Lipid A; C043399:6,6'-dicorynomycolyl trehalose; C048436:monophosphoryl lipid A